Lux Vitae advocates Steriwave for COVID prevention
7th March 2023
(NON_REGULATORY ANNOUNCEMENT)
ONDINE BIOMEDICAL INC.
("Ondine Biomedical", "Ondine" or the "Company")
Lux Vitae advocates Steriwave for COVID prevention
Ondine Biomedical notes that Dr Jack Kolenda of Lux Vitae International yesterday (6th March 2023) held a press briefing on the benefits of Ondine's Steriwave treatment for decolonising the nose in the prevention and treatment of COVID-19.
The press release distributed by Lux Vitae International can be viewed at:
The press conference included verbal presentations from, amongst others:
· Dr Jack Kolenda, ENT surgeon and Medical Director of Verso Surgery and Lux Vitae
· Dr Joseph Argemi, MD, PhD, Internal Medicine Department, University of Navarra1 in Spain
· Gary Segal, Past Chair of Vancouver General Hospital and UBC Foundation
· Professor Trevor Jones, CBE, PhD DSc FRCP FMedSci FBPhS FRSM FRSC FLSW is a visiting professor at King's College London and a former Head of R&D at Wellcome and board member of many healthcare organisations.
· The Manager of KISS, Doc McGhee. Kiss is using Steriwave on their Farewell World Tour.
· Individual users of the Steriwave therapy, including one who participated in a live product use demonstration.
· The President and CTO of the company, Dr. Nick Loebel.
· The Company's founder and CEO, Carolyn Cross.
The press conference was hosted by Rod Black, a well-known Canadian sports announcer.
A video replay of the press conference can be found at:
https://youtube.com/live/i1mqhBY44s8?feature=share
No material new public information was presented or discussed by the Company. The Steriwave treatment is approved in Canada, the European Union, the United Kingdom, Ireland, Australia and Mexico. The Steriwave treatment is not for sale or distribution in the United States; Ondine is in the process of preparing for a Phase 3 clinical study after which it intends to seek appropriate regulatory approval for the use of Steriwave for nasal decolonisation in US hospital settings.
|
Ondine Biomedical Inc. |
|
|
Angelika Vance, Corporate Communications |
+001 (604) 838 2702 |
|
|
|
|
Singer Capital Markets (Nominated Adviser and Joint Broker) |
|
|
Aubrey Powell, Asha Chotai, Sam Butcher |
+44 (0)20 7496 3000 |
|
|
|
|
RBC Capital Markets (Joint Broker) |
|
|
Rupert Walford, Kathryn Deegan |
+44 (0)20 7653 4000 |
|
|
|
|
Vane Percy & Roberts (Media Contact) |
|
|
Simon Vane Percy, Amanda Bernard |
+44 (0)77 1000 5910 |
About Nasal Photodisinfection
Ondine's nasal photodisinfection is a patented technology using a proprietary photosensitiser (non-antibiotic, light-activated solution) to destroy pathogens. The photodisinfection treatment is carried out by a trained healthcare professional, and is an easy to use, painless, two-step process. The photosensitiser is applied to each nostril using a nasal swab, followed by illumination of the area with a specific wavelength of laser light for less than five minutes. The light activates the photosensitiser, causing an oxidative burst that is lethal to all types of pathogens. A key benefit of this approach, unlike with antibiotics, is that pathogens do not develop resistance to the therapy.
Nasal decolonisation with antibiotics is already standard practice in many hospitals prior to surgery, as pathogens in a patient's nasal cavities are a major cause of surgical site infections (SSIs). However, there is a growing need to reduce antibiotic use and find non-antibiotic methods of nasal decolonisation as resistance rates have been reported as high as 81%2.
Ondine's nasal photodisinfection system has a CE mark and is approved in Canada and several other countries under the name Steriwave™. It has been used in Canada for over ten years, with no serious adverse events reported. In the US, it is currently undergoing clinical trials for regulatory approval.
About Ondine Biomedical Inc.
Ondine Biomedical Inc. is a Canadian headquartered life sciences company. Ondine has a pipeline of investigational products, based on its proprietary photodisinfection platform, in various stages of development. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns, and other indications.
2. Journal of Antimicrobial Chemotherapy, Volume 70, Issue 10, October 2015, Pages 2681-2692, https://doi.org/10.1093/jac/dkv169
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 1 day ago Savannah Energy
- 1 day ago Buccaneer Energy PLC
- 1 day ago Savannah Energy
- 1 day ago Carclo
- 1 day ago Schroder Japan Growth Fund